News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 09 - 16

Global Debut! Innova Pharma's YN001 Phase Ib/IIa Clinical Data Presented at ESC 2025 | Feng Investme

On September 1, at the European Society of Cardiology Congress 2025 (ESC Congress 2025) held in Madrid, Spain, the Phase Ib/IIa clinical trial data for YN001, the first innovative drug from Innova Pharma designed to reverse atherosclerotic plaques, was released globally for the first time. A clinical expert representative delivered an oral presentation titled "Active Targeted Liposomal Drug Significantly Reverses Atherosclerotic Plaques: A Proof-of-Concept Phase Ib/IIa Clinical Trial," reporting for the first time the remarkable efficacy and safety results from the YN001 Phase Ib/IIa...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 12

The Only Anemia Treatment for Chronic Kidney Disease Supporting Weekly Oral Dosing Globally! First-i

On September 11, the official website of the Clinical Trial Registration and Information Platform showed that Andao Pharmaceuticals registered a Phase III clinical trial for oral AND017 capsules in subjects with anemia due to dialysis-dependent chronic kidney disease (DD-CKD). Public information indicates this is the first Phase III trial initiated for this drug.Screenshot source: Clinical Trial Registration and Information PlatformThis is a multicenter, randomized, open-label, active-controlled, parallel-group Phase III clinical trial designed to evaluate the efficacy and safety of AND017 in ...

浏览次数：0

查看详情>>

发布时间: 2025 - 09 - 11

First Global Study of Utidelone Capsules Initiated | Dosing of Patients in Phase II/III Clinical Tri

On September 11, 2025, Beijing Huahaizhongtian Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huahaizhongtian," stock code: 2563.HK) announced that the first patient has been dosed in an international multicenter Phase II/III clinical study (BG02-2502) evaluating Utidelone capsules (UTD2) for the treatment of patients with platinum-resistant advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This is the first international multicenter clinical study initiated globally for UTD2 in the treatment of advanced solid tumors, followi...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 08

Xinyuan Pharmaceutical's Anti-Gout Innovative Drug ABP-671 Achieves Positive Results in Global Phase

On September 8, 2025, according to information from Hangzhou, Zhejiang, and the United States, Xinyuan Pharmaceutical announced very positive results from the global Phase IIb/III clinical trial of ABP-671 for the treatment of gout. This study was a multicenter, randomized, double-blind, allopurinol-positive (Treat-to-Target) and placebo-controlled global study conducted across multiple countries and regions, including the United States, Europe, Australia, Latin America, and Taiwan, with a 6-month primary endpoint evaluation period.The results showed that this clinical trial met all primary an...

浏览次数：0

查看详情>>